The Cytotoxic Effects of Preserved and Preservative-Free Prostaglandin Analogs on Human Corneal and Conjunctival Epithelium In Vitro and the Distribution of Benzalkonium Chloride Homologs in Ocular Surface Tissues In Vivo

REFERENCES

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol, 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs Aging, 2003;20:597–630.
   PubMed Web of Science ®Google Scholar
• Waugh J, Jarvis B. Travoprost. Drugs Aging, 2002;19:465–71; discussion 472.
   Google Scholar
• Cantor LB. Clinical pharmacology of bimatoprost. Expert Opin Drug Metab Toxicol, 2005;1:151–157.
   PubMedGoogle Scholar
• Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: Similarities and differences. Surv Ophthalmol, 2008;53:69–84.
   PubMed Web of Science ®Google Scholar
• Takagi Y, Nakajima T, Shimazaki A et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res, 2004;78:767–776.
   PubMed Web of Science ®Google Scholar
• Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther, 2007;23:359–365.
   PubMed Web of Science ®Google Scholar
• Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther, 2008;46:400–406.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A. Phase III study investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol, 2010;88:12–19.
   PubMed Web of Science ®Google Scholar
• Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther, 2010;26:97–104.
   PubMed Web of Science ®Google Scholar
• Furrer P, Mayer JM, Plazonnet B, Gurny R. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS PharmSci, 2002;4:2.
   Google Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther, 2001;18:205–215.
   PubMed Web of Science ®Google Scholar
• Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology, 1992;99:1082–1088.
   PubMed Web of Science ®Google Scholar
• Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci, 1980;19:308–313.
   PubMed Web of Science ®Google Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: Implications for the treatment of glaucoma. Acta Ophthalmol, 2008;86:716–726.
   PubMed Web of Science ®Google Scholar
• Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther, 2009;25:113–119.
   PubMed Web of Science ®Google Scholar
• Euerby MR. High performance liquid chromatography of benzalkonium chlorides–variation in commercial preparations. J Clin Hosp Pharm, 1985;10:73–77.
   PubMedGoogle Scholar
• Smith MJ, Flowers TH, Cowling MJ, Duncan HJ. Method for the measurement of the diffusion coefficient of benzalkonium chloride. Water Res, 2002;36:1423–1428.
   Google Scholar
• Herman JR, Bass P. Enteric neuronal ablation: Structure-activity relationship in a series of alkyldimethylbenzylammonium chlorides. Fundam Appl Toxicol, 1989;13:576–584.
   Google Scholar
• Prince SJ, McLaury HJ, Allen LV, McLaury P. Analysis of benzalkonium chloride and its homologs: HPLC versus HPCE. J Pharm Biomed Anal, 1999;19:877–882.
   PubMedGoogle Scholar
• Adriaens E, Dierckens K, Bauters TG et al. The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs. Pharm Res, 2001;18:937–942.
   PubMed Web of Science ®Google Scholar
• Erhart M, Zilliox P, De Burlet GL, Andermann G. Differences in ocular toxicity and antimicrobial activity of benzalkonium chlorides. Concepts Toxicol, 1987;4:145–151.
   Google Scholar
• Daoud NN, Dickinson NA, Gilbert P. Antimicrobial activity and physico-chemical properties of some alkyldimethylbenzylammonium chlorides. Microbios, 1983;37:73–85.
   PubMedGoogle Scholar
• Araki-Sasaki K, Ohashi Y, Sasabe T et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci, 1995;36:614–621.
   PubMed Web of Science ®Google Scholar
• Diebold Y, Calonge M, Enríquez de Salamanca A et al. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest Ophthalmol Vis Sci, 2003;44:4263–4274.
   PubMed Web of Science ®Google Scholar
• Green K, Chapman J, Cheeks L, et al. Detergent penetration into young and adult rabbit eyes: Comparative pharmacokinetics. J Toxicol-Cut & Ocular Toxicol, 1987;6:89–107.
   Web of Science ®Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf, 2007;6:45–52.
   PubMed Web of Science ®Google Scholar
• Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol, 2003;14:65–69.
   PubMedGoogle Scholar
• Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea, 2008;27:339–343.
   PubMed Web of Science ®Google Scholar
• Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther, 2006;23:663–671.
   PubMed Web of Science ®Google Scholar
• McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. J Ocul Pharmacol Ther, 2007;23:445–451.
   PubMed Web of Science ®Google Scholar
• Spielmann H. White Paper of the European Commission–strategy for a new chemicals policy. Altex, 2002;19:20–25.
   Google Scholar
• Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther, 2006;23:511–519.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci, 2007;48:4123–4128.
   PubMed Web of Science ®Google Scholar
• Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci, 2005;46:4594–4599.
   PubMed Web of Science ®Google Scholar
• Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci, 2005;46:2444–2450.
   PubMed Web of Science ®Google Scholar
• Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol, 2003;121:835–839.
   PubMed Web of Science ®Google Scholar
• Hamard P, Blondin C, Debbasch C, Warnet JM, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol, 2003;241:1037–1043.
   PubMed Web of Science ®Google Scholar
• Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res, 2008;33:303–312.
   PubMed Web of Science ®Google Scholar
• Uematsu M, Kumagami T, Shimoda K et al. Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity. Cornea, 2010;29:1296–1301.
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol, 2008;92:1275–1282.
   PubMed Web of Science ®Google Scholar
• Baudouin C. The ocular surface in glaucoma. Cornea, 2009;28:14–18.
   PubMed Web of Science ®Google Scholar
• Hommer A. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension. Drugs Today, 2010;46:409–416.
   PubMed Web of Science ®Google Scholar
• Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf), 2008;242:14–19.
   PubMedGoogle Scholar
• Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res, 2009;41:118–122.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol, 2010;88:329–336.
   PubMed Web of Science ®Google Scholar
• Champeau EJ, Edelhauser HF. Effect of ophthalmic preservatives on the ocular surface. conjunctival and corneal uptake of benzalkoium chloride and chlorhexidine digluconate. In: Holly FJ, editor. The preocular tear film in health, disease and contact lens wearers. Dry Eye Inst (November 1986), Lubbock, TX 1986 p. 292–302.
   Google Scholar